Eli Lilly and Co (LLY) (Q3 2026) Earnings Call Highlights: Revenue Jumps 39% as Mounjaro
Eli Lilly (NYSE:LLY) reported Q3 2026 revenue of $7B, up 39% YoY, driven by Mounjaro and Zepbound. The company raised full-year revenue guidance to $91-$92B and EPS guidance to $35-$36. Positive factors included the Medicare GLP-1 Bridge Program and pipeline advancements, while challenges included US price declines and potential future headwinds. Management highlighted long-term growth opportunities and increased manufacturing investments.
How this was made
The 30-second read
Why it matters
The most tradable elements are the explicit guidance increases for 2026 and the quantified Bridge uptake and patient selection metrics, which directly affect near-term revenue expectations. Offsetting factors include US net price declines and management’s view that net realized price remains a headwind in 2027, plus durability risks tied to oral adherence and discontinuation in higher-dose EloraTZP.
Market read
Traders can update models immediately using the raised 2026 guidance and the call’s quantified access and adoption metrics, while also stress-testing 2027 earnings sensitivity to net realized price declines and channel mix.
What to watch
Oral GLP-1 adherence is expected to be lower than weekly injectables, and higher discontinuation rates in the highest-dose EloraTZP arm could constrain longer-term durability versus current expectations.
Background
This is a Q3 2026 earnings call highlights recap for Eli Lilly, covering revenue growth drivers, raised full-year guidance, Medicare GLP-1 Bridge performance, pipeline updates, and 2027 pricing headwinds.
Ticker impact
Lilly raised full-year 2026 revenue guidance to $91-$92B and EPS to $35-$36, citing Mounjaro and Zepbound momentum plus Medicare GLP-1 Bridge uptake.
Likely upward bias as traders price in higher 2026 growth, tempered by concerns that 2027 net realized price remains a headwind.
The article provides explicit, time-relevant guidance increases and concrete demand/access metrics (Bridge prescriptions, patient choice, oral launch share), alongside specific negative pricing commentary for 2027.
Market effects
Reinforces GLP-1 category demand durability and payer access expansion, while highlighting ongoing pricing pressure dynamics that may influence sector valuation multiples.
Emphasizes Medicare/Medicaid mix shift in the US and disciplined ex-US pricing, which can affect regional reimbursement expectations for obesity therapies.
Supports the broader global obesity-pharma growth narrative, but flags that net pricing and channel mix remain key cross-market variables for earnings durability.
Counterpoint
The guidance raise may be partly offset by non-recurring items and worsening net realized pricing assumptions, so upside could fade if 2027 pricing pressure materializes faster than expected.
Key entities
- companyEli Lilly and Co
Raised full-year 2026 revenue and non-GAAP EPS guidance; discussed Medicare GLP-1 Bridge uptake, oral launch progress, pipeline Phase 3 data, and 2027 pricing headwinds.
- productMounjaro
Cited as a key driver of revenue growth and momentum in the quarter.
- productZepbound
Cited as a key driver of revenue growth and momentum in the quarter.
- programMedicare GLP-1 Bridge Program
Expanded access to obesity medicines for about 20 million seniors, with over 0.5 million prescriptions filled and strong Lilly medicine selection.
- pipeline_assetretatrutide
Reported positive Phase 3 data with greater A1C reduction and more than double weight loss vs semaglutide (as described in the call highlights).
